logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Carcinoma Nonsmallcell Lung

    FiltersReset Filters
    17 results

    • bizengri

      (Zenocutuzumab)
      Merus US, Inc.
      Usage: BIZENGRI is indicated for adults with advanced unresectable or metastatic non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma that possess a neuregulin 1 (NRG1) gene fusion and have progressed after prior systemic therapy. Approval is based on overall response rate and duration of response.

    • docetaxel

      (Docetaxel)
      Dr. Reddy's Laboratories Inc.
      Usage: Docetaxel injection is indicated for treating locally advanced or metastatic breast, non-small cell lung, prostate, gastric adenocarcinoma, and head and neck cancers. It is used alone or in combination with other drugs, primarily after prior chemotherapy failure or for adjuvant treatment in certain patients.

    • docetaxel

      (Docetaxel)
      Mylan Institutional LLC
      Usage: Docetaxel Injection is indicated for treating locally advanced or metastatic breast cancer, non-small cell lung cancer, metastatic castration-resistant prostate cancer, advanced gastric adenocarcinoma, and locally advanced head and neck cancer, often in combination with other chemotherapy agents, after prior treatments have failed.

    • docetaxel

      (Docetaxel)
      Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
      Usage: Docetaxel Injection is indicated for treating locally advanced or metastatic breast cancer, non-small cell lung cancer, metastatic castration-resistant prostate cancer, advanced gastric adenocarcinoma, and locally advanced squamous cell carcinoma of the head and neck, often in combination with other chemotherapeutic agents.

    • docetaxel

      (Docetaxel)
      Gland Pharma Limited
      Usage: Docetaxel Injection is indicated for treating locally advanced or metastatic breast cancer after prior chemotherapy, non-small cell lung cancer post platinum-based therapy, metastatic castration-resistant prostate cancer with prednisone, advanced gastric adenocarcinoma, and induction therapy for locally advanced squamous cell carcinoma of the head and neck.

    • docetaxel

      (Docetaxel)
      Eugia US LLC
      Usage: Docetaxel injection is indicated for treating locally advanced or metastatic breast, non-small cell lung, prostate, gastric, and head and neck cancers, often in combination with other chemotherapeutic agents. It is used after prior chemotherapy failures or for patients who have not previously received treatment for certain conditions.

    • docetaxel anhydrous

      (Docetaxel anhydrous)
      Meitheal Pharmaceuticals Inc
      Usage: Docetaxel Injection is indicated for locally advanced or metastatic breast cancer, non-small cell lung cancer, metastatic castration-resistant prostate cancer, advanced gastric adenocarcinoma, and head and neck cancer. It is used as a single agent or in combination with other chemotherapeutic agents based on specific patient conditions.

    • erlotinib

      (ERLOTINIB)
      Camber Pharmaceuticals, Inc.
      Usage: Erlotinib tablets are indicated for treating metastatic non-small cell lung cancer (NSCLC) in patients with specific EGFR mutations and for first-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer when combined with gemcitabine. Not recommended for NSCLC with other EGFR mutations or with platinum-based chemotherapy.

    • gefitinib

      (Gefitinib)
      Apotex Corp.
      Usage: Gefitinib tablets are indicated as a first-line treatment for metastatic non-small cell lung cancer (NSCLC) in patients with tumors that have EGFR exon 19 deletions or exon 21 (L858R) mutations. Safety and efficacy in other EGFR mutations have not been established.

    • gemcitabine

      (GEMCITABINE HYDROCHLORIDE)
      Meitheal Pharmaceuticals Inc.
      Usage: Gemcitabine for injection is indicated for advanced ovarian cancer (post-platinum therapy), metastatic breast cancer (after anthracycline failure), inoperable non-small cell lung cancer, and as first-line treatment for locally advanced or metastatic pancreatic adenocarcinoma.